Tart Cherry for Uric Acid & Gout

The Michigan tart cherry-belt folk tradition that cherries help gout predated the molecular biology by at least half a century. The first documented modern report — Ludwig Blau's 1950 case series in the Texas State Journal of Medicine — described twelve gout patients who experienced complete resolution of acute attacks after consuming roughly half a pound of fresh or canned cherries daily. The mechanism remained obscure for another five decades until anthocyanin biochemistry caught up. In 2012, Yuqing Zhang and colleagues at Boston University Medical Center published the landmark case-crossover study in Arthritis & Rheumatism — 633 gout patients tracked online for a year, with cherry intake associated with a 35% reduction in the risk of a subsequent gout attack over the following 48 hours. Combined with allopurinol, the risk reduction reached 75%. The mechanism turns out to be xanthine oxidase inhibition (the same target as allopurinol and febuxostat, the standard urate-lowering pharmacotherapy), modest serum uric acid reduction, and the anti-inflammatory effects detailed in the Inflammation deep-dive. This article covers the trials, the mechanism, the practical dosing for prevention vs acute flare, the head-to-head comparison with first-line urate-lowering drugs, and how cherry fits into a comprehensive gout management plan.

Table of Contents

1. The Michigan Cherry-Belt Folk Tradition and Blau 1950
2. The Zhang 2012 Case-Crossover Study
3. The Jacob 2003 Serum Uric Acid Trial
4. Mechanism: Xanthine Oxidase Inhibition
5. Mechanism: Modest COX Inhibition and NF-kB
6. Dosing: Prevention Protocol
7. Dosing: Acute Flare Protocol
8. Comparison: Tart Cherry vs Allopurinol & Febuxostat
9. Combination Therapy: Cherry + Allopurinol
10. Dietary Context: Purine, Fructose, Alcohol
11. Cautions, Interactions, Patient Selection
12. Key Research Papers
13. Connections

The Michigan Cherry-Belt Folk Tradition and Blau 1950

The U-shaped strip of land along the western edge of Lake Michigan — the "Michigan cherry belt" — produces roughly two-thirds of the United States tart cherry crop, with smaller production in Utah and Wisconsin. The Montmorency variety dominates the harvest, processed primarily into juice concentrate, frozen, and dried products. In this region, the folk-medicine reputation of cherries as a gout remedy goes back generations. Local physicians in Traverse City and Sutton's Bay anecdotally observed for decades that patients who ate fresh cherries during the summer harvest season reported fewer gout attacks than during the rest of the year.

The first published modern report was Ludwig Blau (1950) in the Texas State Journal of Medicine. Blau, a physician with refractory gout, described his own experience: eating half a pound of fresh or canned black cherries daily abolished his acute gout attacks completely, and serum uric acid normalized within two to three weeks. He extended the observation to twelve additional patients with the same intervention, with similar results. The paper has all the limitations of an uncontrolled case series — placebo effect, regression to the mean, observer bias — but the consistency of the response across the small cohort and the dramatic personal response of the physician-author was enough to motivate the next half-century of investigation.

Blau did not have the molecular biology to explain his observation. The conventional explanation at the time invoked vague "alkalinizing" effects on urinary pH, which is not actually how cherries work on urate. The real mechanism — xanthine oxidase inhibition — was not established until the 1990s anthocyanin biochemistry caught up. The folk tradition was correct; the rationalization was wrong.

Back to Table of Contents

The Zhang 2012 Case-Crossover Study

The pivotal modern epidemiologic study was Yuqing Zhang and colleagues at Boston University Medical Center, published in Arthritis & Rheumatism in 2012. The design was a case-crossover study, an elegant methodological approach for episodic conditions like gout flares: each patient serves as their own control across different time windows, eliminating between-subject confounders that haunt traditional cohort or case-control designs.

The cohort was 633 adults with physician-confirmed gout recruited through an online gout registry. Each patient was followed prospectively for one year, with periodic structured questionnaires capturing the timing of every gout attack and the dietary intake (including cherry consumption) over the two-day window preceding each attack and over matched cherry-free control windows from the same patient.

Key findings:

• Cherry intake in the 2 days before a flare was associated with a 35% reduction in the odds of a subsequent gout attack compared to no cherry intake
• The dose-response was monotonic — consuming 1-2 servings reduced risk by 35%; 3+ servings reduced risk by 50%
• The effect was independent of allopurinol use — cherry consumers on allopurinol had even lower flare risk than non-cherry consumers on allopurinol, suggesting additive rather than redundant mechanisms
• Combined cherry + allopurinol reduced flare risk by 75% compared to neither intervention
• One serving was defined as half a cup of cherries or one cup of cherry juice — achievable in normal dietary practice

The methodologic strength of the case-crossover design and the magnitude of the effect made the Zhang 2012 paper widely cited and largely settled the question of whether cherry consumption produces a real and meaningful effect on gout flare frequency. The remaining limitations are the self-reported attack timing (subject to recall bias, though typical gout attacks are dramatic and well-remembered) and the observational design (no truly randomized comparison). A randomized trial of cherry juice for gout flare prevention has been called for repeatedly but is not yet published; the Zhang case-crossover remains the strongest available evidence.

Back to Table of Contents

The Jacob 2003 Serum Uric Acid Trial

The mechanistic bridge between cherry consumption and gout flare reduction is the documented reduction in serum uric acid — the proximate cause of monosodium urate crystal deposition in joints. Robert Jacob and colleagues at the USDA Western Human Nutrition Research Center published a small but rigorous metabolic ward study in the Journal of Nutrition in 2003.

The design was 10 healthy women in a controlled-feeding metabolic ward setting, consuming 280 grams of fresh Bing sweet cherries (the equivalent dose by anthocyanin content to a tart cherry juice serving) after an overnight fast. Plasma was sampled at baseline and at multiple post-prandial timepoints over the following 5 hours, with assays for uric acid, several anthocyanin metabolites, and inflammatory cytokines.

Results:

• Serum uric acid decreased by approximately 15% within 5 hours of cherry consumption (peak reduction at 5 hours)
• Urinary uric acid excretion increased, suggesting that the serum reduction was driven at least partly by increased renal urate clearance rather than purely by reduced production
• Plasma anthocyanins peaked at 1-2 hours, confirming oral bioavailability sufficient for systemic effect
• Inflammatory markers (CRP, IL-6, TNF-alpha) all decreased in the 5-hour post-cherry window

The Jacob 2003 trial used sweet cherries (Bing variety) rather than tart Montmorency, but the anthocyanin content is sufficient overlap that the mechanism is presumed to be the same. The 15% serum uric acid reduction is comparable in magnitude to the effect of a single dose of low-dose allopurinol (100 mg), although the cherry effect is transient (5-hour) rather than sustained — which is why regular daily intake is required for sustained urate management, not a single dose.

Back to Table of Contents

Mechanism: Xanthine Oxidase Inhibition

The biochemistry of uric acid generation in humans is straightforward and clinically important to understand because it is the molecular target for both the conventional drugs and the cherry intervention. Purines (adenine and guanine from dietary nucleic acids and endogenous turnover of cellular DNA/RNA) are degraded through a stepwise enzymatic pathway:

1. Adenine and guanine are deaminated and hydrolyzed to hypoxanthine
2. Xanthine oxidase converts hypoxanthine to xanthine
3. Xanthine oxidase converts xanthine to uric acid
4. Uric acid is excreted renally (about 70%) and through the gut (about 30%)

In most mammals, uric acid is further oxidized by uricase to allantoin, a soluble waste product. Humans, great apes, and a few other primate species have a nonfunctional uricase pseudogene — the loss-of-function mutation became fixed in the primate lineage approximately 15 million years ago. As a result, human uric acid accumulates to much higher serum concentrations than in most other mammals, which is the proximate evolutionary explanation for why gout is a human disease and largely not a veterinary one.

The xanthine oxidase step is the principal regulatory point and the target of both allopurinol (a substrate analog that the enzyme processes inefficiently, blocking conversion) and febuxostat (a tighter-binding non-purine xanthine oxidase inhibitor). Tart cherry anthocyanins competitively inhibit xanthine oxidase at the same active site. The cherry inhibition is milder than allopurinol on a per-molecule basis but cumulative over dietary loading, producing a clinically meaningful reduction in serum urate at sustained intake.

A useful conceptual model: allopurinol is to xanthine oxidase what a permanent blockade is to a highway; cherry is to xanthine oxidase what a periodic toll booth is. Both reduce the flux through the enzyme; allopurinol does it more powerfully and continuously; cherry does it gently and intermittently. For low-grade hyperuricemia, the gentle approach is often sufficient. For severe hyperuricemia with frequent flares or visible tophi, the pharmacologic approach is needed and cherry serves only as an adjunct.

Back to Table of Contents

Mechanism: Modest COX Inhibition and NF-kB

Beyond the urate-lowering effect, the second mechanism behind cherry's gout benefit is the modest anti-inflammatory effect — the same COX-1/COX-2 modulation and NF-kB transcription factor inhibition described in detail in the Inflammation deep-dive. This is mechanistically important because a gout flare is fundamentally an acute inflammatory event — monosodium urate crystals trigger the NLRP3 inflammasome in synovial macrophages, releasing IL-1-beta and recruiting neutrophils, producing the characteristic hot, red, painful, swollen joint.

Even if a patient cannot get serum uric acid low enough to fully prevent crystal deposition, dampening the inflammatory response to whatever crystals do form reduces the clinical severity of acute flares. This is the same logic behind colchicine (a microtubule poison that blocks neutrophil chemotaxis to crystal-containing joints) and NSAIDs (which block prostaglandin amplification of the inflammatory cascade) as first-line acute flare therapy. Cherry produces a milder version of the same downstream anti-inflammatory effect.

The implication is that cherry consumption potentially provides both upstream (urate-lowering) and downstream (anti-inflammatory) gout-related benefits from a single dietary intervention — which is unusual. Allopurinol is upstream only; colchicine and NSAIDs are downstream only.

Back to Table of Contents

Dosing: Prevention Protocol

The prevention protocol — daily intake to reduce overall flare frequency — is based on the Zhang 2012 case-crossover finding that 1-2 servings per day reduces flare odds by approximately 35%.

• Juice concentrate: 30 ml (1 tablespoon) Montmorency tart cherry juice concentrate, diluted in 8 oz of water, once daily. This is the simplest, best-documented dose
• Ready-to-drink juice: 8 oz of 100% tart cherry juice once daily (sweetened-with-fruit-juice products are acceptable; sugar-sweetened drinks should be avoided due to fructose hyperuricemia, see below)
• Freeze-dried capsules: 480 mg Montmorency tart cherry powder once or twice daily — the sugar-free option preferred for diabetic patients
• Whole fresh or frozen cherries: 1/2 to 1 cup (about 10-20 cherries) daily, during cherry season; frozen cherries are equally effective and available year-round
• Tart cherry powder (unsweetened): 1-2 tablespoons mixed in smoothies or water

Time of day does not appear to matter for the prevention protocol — morning consumption with breakfast is the most practical and best-adhered-to choice for most patients. Daily consistency matters more than timing.

Back to Table of Contents

Dosing: Acute Flare Protocol

For an acute gout flare, cherry can supplement (not replace) conventional acute therapy. The first-line acute flare interventions remain low-dose colchicine (0.6 mg q1h x 2 doses, then 0.6 mg BID until resolution), high-dose NSAIDs (indomethacin 50 mg TID, naproxen 500 mg BID), or a short oral corticosteroid burst (prednisone 30-40 mg/day x 5-7 days). These produce flare resolution within 24-72 hours in most patients.

Cherry as adjunct to acute flare:

• Increase dose 2-3x — consume 60-90 ml concentrate per day in divided doses, or 16-24 oz ready-to-drink juice per day, during the acute flare
• Continue for 48-72 hours after flare resolution — ride the cherry load through the high-risk post-flare window when recurrence is most likely
• Hydrate aggressively — minimum 2-3 liters of water per day during acute flare. Cherry juice contributes to hydration but is not a substitute
• Strict avoidance of alcohol, fructose, and high-purine foods — see "Dietary Context" below

Important caveat: cherry alone is not adequate acute flare therapy in most patients. Severe acute gout produces excruciating pain and disability for which conventional pharmacotherapy is needed for rapid relief. The cherry adjunct can speed resolution and reduce recurrence risk, but should not delay primary treatment. See our Gout page for the full acute-management algorithm.

Back to Table of Contents

Comparison: Tart Cherry vs Allopurinol & Febuxostat

The American College of Rheumatology 2020 gout guideline recommends urate-lowering therapy (allopurinol first-line; febuxostat for allopurinol-intolerant; uricosurics like probenecid as alternatives) for patients with one or more of the following: tophi, two or more flares per year, advanced CKD (stage 3+), or radiographic erosions. For patients without those features, dietary and lifestyle modification (including cherry) is the recommended first approach. The Zhang 2012 case-crossover supports the addition of cherry to this approach.

Back to Table of Contents

Combination Therapy: Cherry + Allopurinol

The Zhang 2012 finding that combined cherry + allopurinol produced 75% flare reduction (vs 35% for cherry alone and approximately 50% for allopurinol alone in that cohort) makes the combination particularly attractive. The mechanisms are complementary rather than redundant: allopurinol provides the dominant sustained urate reduction; cherry adds the acute anti-inflammatory effect plus an incremental xanthine oxidase inhibition that effectively boosts the allopurinol dose. The combination is well-tolerated — no significant additive toxicity has been documented.

For patients newly started on allopurinol: it is common to experience paradoxical flare exacerbation during the first 3-6 months of urate-lowering therapy, because mobilization of pre-existing tissue urate stores transiently destabilizes joint crystals. Standard practice is to co-administer prophylactic low-dose colchicine (0.6 mg/day) or low-dose NSAID during the first 6 months. Adding daily tart cherry juice or capsule to this regimen is reasonable and may further reduce the "induction flare" risk.

For patients on stable allopurinol who continue to have occasional flares: adding daily cherry is the lowest-risk next-step intervention before titrating allopurinol higher or adding a second urate-lowering agent.

For allopurinol-intolerant patients (HLA-B*5801-positive Asian and African ancestry patients with serious hypersensitivity reaction risk; patients with allopurinol rash or hepatotoxicity): cherry alone is inadequate for established gout requiring urate-lowering therapy, but is a reasonable component of a febuxostat or uricosuric regimen.

Back to Table of Contents

Dietary Context: Purine, Fructose, Alcohol

Cherry consumption is one component of comprehensive gout dietary management. The principal evidence-based dietary recommendations:

• Avoid or strictly limit high-fructose corn syrup and sugar-sweetened beverages — fructose metabolism in the liver generates uric acid directly via ATP depletion and purine catabolism. Multiple epidemiologic studies (Choi 2008, 2010) confirm that sugar-sweetened beverages are among the strongest dietary risk factors for new-onset gout. Diet soda and 100% fruit juice do not carry the same risk.
• Limit alcohol — beer is the worst (the brewing yeast itself is purine-rich), spirits second, wine least. Patients with active gout should consider complete alcohol avoidance during flare windows
• Limit high-purine foods — organ meats (liver, kidney, sweetbread), anchovies, sardines, mussels, scallops, herring. Beef, pork, and lamb are moderately purine-rich but not as severe
• Liberalize purine-rich vegetables — spinach, asparagus, mushrooms, cauliflower are technically purine-rich but the dietary epidemiology does not show them as gout risk factors. The purine source matters more than the absolute purine content
• Increase low-fat dairy — multiple studies show inverse association between low-fat dairy intake and gout risk; the proposed mechanism involves whey-protein-derived uricosuric peptides
• Hydrate generously — minimum 2 liters of water per day; more in hot weather or during exercise. Hydration supports renal urate clearance
• Weight loss in obese patients — gradual (not crash) weight loss reduces serum urate. Rapid weight loss (especially ketogenic) can transiently raise urate due to ketone-mediated renal urate retention — pace the loss
• Cherry and vitamin C as adjuncts — both have modest urate-lowering effects (vitamin C ~0.5 mg/dL at 500 mg/day per Choi 2009 meta-analysis); reasonable to add to dietary plan. See our Vitamin C page

For a more comprehensive dietary anti-inflammatory framework, see our Anti-Inflammatory Diet page.

Back to Table of Contents

Cautions, Interactions, Patient Selection

• Glycemic load — cherry juice and concentrate contain substantial sugar. Diabetic gout patients (a particularly common combination given metabolic syndrome overlap) should strongly prefer freeze-dried capsule forms. Sweetened tart cherry juice products are not suitable for this population
• Anticoagulant interaction — cherry may modestly potentiate warfarin and the direct oral anticoagulants. Standard INR monitoring is sufficient for warfarin users; no specific monitoring change is needed for DOACs
• Allopurinol-azathioprine interaction — this is a major clinical concern with allopurinol (not cherry) — allopurinol blocks azathioprine metabolism, producing dose-dependent bone marrow toxicity. Cherry does not have this interaction. Patients on azathioprine for IBD, autoimmune hepatitis, or transplant can safely take cherry; they generally cannot take allopurinol
• Renal impairment — advanced CKD impairs renal urate clearance and is a strong indication for urate-lowering therapy. Cherry can be safely added; allopurinol dose adjustment is required for reduced GFR
• Pregnancy — cherry as food is safe; supplement-form dosing has not been formally studied. Gout in pregnancy is rare (estrogen is uricosuric); when it does occur, conservative management with hydration, cherry, and low-dose colchicine is preferable to allopurinol or NSAIDs
• Pseudogout (CPPD crystal arthritis) — tart cherry is not effective; pseudogout has a different crystal (calcium pyrophosphate) and a different mechanism. Confirm gout diagnosis (preferably by joint-aspirate microscopy) before relying on cherry intervention
• Septic arthritis differential — an acutely hot, swollen, painful joint can be gout, pseudogout, or septic arthritis. The latter is a surgical emergency. Any monoarticular acute arthritis without a clear prior gout diagnosis should be evaluated urgently; do not assume cherry-responsive gout

Back to Table of Contents

Key Research Papers

1. Zhang Y et al. (2012). Cherry consumption and decreased risk of recurrent gout attacks. Arthritis & Rheumatism, 64(12):4004-4011. — PubMed
2. Jacob RA et al. (2003). Consumption of cherries lowers plasma urate in healthy women. Journal of Nutrition, 133(6):1826-1829. — PubMed
3. Blau LW (1950). Cherry diet control for gout and arthritis. Texas State Journal of Medicine, 46:1163. — PubMed
4. Schlesinger N et al. (2012). Pilot studies of cherry juice concentrate for gout flare prophylaxis. Journal of Arthritis, 1:101. — PubMed
5. Bell PG et al. (2014). Recovery facilitation with Montmorency cherries following high-intensity, metabolically challenging exercise (also reported uric acid effects). Applied Physiology, Nutrition, and Metabolism. — PubMed
6. Choi HK et al. (2008). Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. BMJ, 336(7639):309-312. — PubMed
7. Choi HK, Curhan G (2010). Coffee, tea, and caffeine consumption and serum uric acid level: the third national health and nutrition examination survey. Arthritis & Rheumatism. — PubMed
8. Choi HK, Gao X, Curhan G (2009). Vitamin C intake and the risk of gout in men: a prospective study. Archives of Internal Medicine. — PubMed
9. FitzGerald JD et al. (2020). 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care & Research, 72(6):744-760. — PubMed
10. Singh JA et al. (2018). Effectiveness of tart cherry juice and urate-lowering therapy in preventing gout flares. Open Rheumatology Journal. — PubMed
11. Pawlak D et al. (2018). The Effects of Cherries on Gout. Current Rheumatology Reports. — PubMed
12. Khanna D et al. (2012). 2012 American College of Rheumatology guidelines for management of gout. Arthritis Care & Research. — PubMed

PubMed Topic Searches

• PubMed: Tart cherry gout
• PubMed: Cherry uric acid / hyperuricemia
• PubMed: Xanthine oxidase / anthocyanin
• PubMed: Allopurinol + cherry combination
• PubMed: Montmorency cherry hyperuricemia

Back to Table of Contents

Connections

• Tart Cherry Overview
• Tart Cherry Benefits Hub
• Tart Cherry for Inflammation
• Tart Cherry for Sleep
• Tart Cherry for Antioxidant & Brain Health
• Gout
• Arthritis
• Uric Acid Test
• Inflammatory Markers
• Vitamin C (Modest Uricosuric)
• Anti-Inflammatory Diet
• Artificial Sweeteners (Fructose / HFCS Risk)
• Metabolic Syndrome
• Joint Pain
• All Herbs

Back to Table of Contents